Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579417 · ClinicalTrials.gov registry record
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- 500
- Enrollment target
- 5
- Study locations
NCT06579417 is a study of Prostate Cancer that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 500 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06579417, a study of Prostate Cancer, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 clinical centers (100 participants per center). The current standard MRI technique for prostate cancer screening is multiparametric MRI (mpMRI), but two drawbacks include need for intravenous (IV) contrast and dependence on radiologist expertise. The investigators expect that the combination of two other techniques, biparametric MRI (bpMRI) and Restriction Spectrum Imaging restriction score (RSIrs), will help non-expert radiologists achieve similar performance to expert radiologists using bpMRI or mpMRI for detection of csPCa, while avoiding the drawbacks that are present when using mpMRI.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST RSI MRI
Study Locations (5)
California
- University of California San Diego - San Diego
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Weill Cornell Medical College - New York
Cambridgeshire
- Cambridge University Hospitals NHS Foundation Trust - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2029-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579417
The ClinicalTrials.gov registry entry for NCT06579417 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which RSI MRI is the first listed.
NCT06579417 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06579417 about?
NCT06579417 is a clinical study titled "ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer". This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 clinical centers (100 participants per center). The current standard MRI technique for prostate cancer ...
What is the current status of trial NCT06579417?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-12-15. Estimated completion is 2029-07.
What conditions does trial NCT06579417 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06579417?
The interventions under investigation include: RSI MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06579417?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06579417 being conducted?
This trial has 5 study locations across California, Massachusetts, New York, Cambridgeshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.